Sage Therapeutics Stock Remains an Exciting Prospect for Investors to Watch Closely

Photo of author
Written By Marcus Reynolds

Sage Therapeutics operates in the biotech sector, with ongoing trials targeting conditions like essential tremor, cognitive impairment, and postpartum depression.

Recent developments, including disappointing trial results, have impacted investor sentiment. However, upcoming data releases present opportunities for the company to rebound.

Overview of Challenges

Credits: DepositPhotos

The failure of SAGE-718 in the phase 2 PRECEDENT Study for PD and slow sales of Zurzuvae for postpartum depression have raised concerns about Sage Therapeutics’ product pipeline and revenue generation.

Amidst these challenges, the company’s performance hinges on the success of ongoing trials, particularly the phase 2b KINETIC 2 Study evaluating SAGE-324 for essential tremor.

Milestones and Expectations

Sage Therapeutics anticipates significant data releases in 2024, including top-line results from various trials:

  • Phase 3 SURVEYOR study for cognitive impairment in Huntington’s Disease (HD) patients.
  • Phase 2 DIMENSION study for cognitive impairment in HD patients.
  • Phase 2 LIGHTWAVE Study for mild cognitive impairment or mild dementia due to Alzheimer’s Disease. The outcome of these trials will likely influence investor confidence and shape the company’s future trajectory.

Analysis of Key Trials

The upcoming phase 2b KINETIC 2 Study for essential tremor treatment is crucial for Sage Therapeutics. The company’s FDA-approved drug, Zurzuvae, has seen sluggish sales to date, underscoring the importance of successful trial outcomes in boosting shareholder value.

However, previous setbacks with SAGE-718 raise doubts about the company’s ability to deliver positive results in cognitive impairment trials.

Financial Position

Sage Therapeutics reported cash reserves of $717 million as of March 31, 2024. While this provides a buffer for operations, slow revenue growth from Zurzuvae and the absence of collaboration revenue pose challenges.

The company’s cash burn rate necessitates prudent financial management and successful trial outcomes to sustain operations.

Several risks could impact Sage Therapeutics’ future performance:

  1. Uncertainty surrounding the success of SAGE-324 in essential tremor treatment.
  2. Sluggish sales of Zurzuvae and revenue-sharing agreements with Biogen.
  3. Potential failures in ongoing cognitive impairment trials with SAGE-718.
  4. Financial constraints and the need for additional funding to support operations beyond the next 12 months.

Outcome of Trials Pending

Investors may want to site on the sidelines and keep a close eye on Sage Therapeutics, pending the outcome of its upcoming trials. Success in the phase 2b KINETIC 2 Study could once again rejuvenate investor confidence and drive share price appreciation.

However, failure to meet expectations in multiple trials would likely dent investor confidence. With significant data readouts expected in 2024, Sage Therapeutics faces a critical juncture in its development journey.

Challenges Lying Ahead

Credits: DepositPhotos

Moreover, Sage Therapeutics faces regulatory and competitive challenges in the biopharmaceutical landscape. Regulatory hurdles, including FDA approvals and compliance requirements, can significantly impact the company’s timeline for product commercialization.

Additionally, competition from established players and emerging biotech firms poses a threat to Sage’s market share and revenue potential. Navigating these obstacles requires strategic decision-making and effective resource allocation to maintain a competitive edge in the evolving healthcare industry.


You should read and understand this disclaimer in its entirety before joining or viewing the website or email/blog list of (the “Publisher”). The information (collectively the “Advertisement”) disseminated by email, text or other method by the Publisher including this publication is a paid commercial advertisement and should not be relied upon for making an investment decision or any other purpose. The Publisher is engaged in the business of marketing and advertising the securities of publicly traded companies in exchange for compensation. The track record, gains, upside, and/or losses mentioned in the Advertisement, if any, should not be considered as true or accurate or be the basis for an investment. The Publisher does not verify the accuracy or completeness of any information included in the Advertisement. While the Publisher does not charge for the SMS service, standard carrier message and data rates may apply. To unsubscribe from receiving promotional text messages to your phone sent via an autodialer, using your phone reply to the sender’s phone number with the word STOP or HELP for help.

The Advertisement is not a solicitation or recommendation to buy securities of the advertised company. An offer to buy or sell securities can be made only by a disclosure document that complies with applicable securities laws and only in the states or other jurisdictions in which the security is eligible for sale. The Advertisement is not a disclosure document. The Advertisement is only a favorable snapshot of unverified information about the advertised company. An investor considering purchasing the securities, should always do so only with the assistance of his legal, tax and investment advisors. Investors should review with his or her investment advisor, tax advisor or attorney, if and to the extent available, any information concerning a potential investment at the web sites of the U.S. Securities and Exchange Commission (the "SEC") at; the Financial Industry Regulatory Authority (the "FINRA") at, and relevant State Securities Administrator website and the OTC Markets website at The Publisher cautions investors to read the SEC advisory to investors concerning Internet Stock Fraud at, as well as related information published by the FINRA on how to invest carefully. Investors are responsible for verifying all information in the Advertisement. As an advertiser, we do not verify any information we publish. The Advertisement should not be considered true or complete.

The Publisher does not offer investment advice or analysis, and the Publisher further urges you to consult your own independent tax, business, financial and investment advisors concerning any investment you make in securities particularly those quoted on the OTC Markets. Investing in securities is highly speculative and carries an extremely high degree of risk. You could lose your entire investment if you invest in any company mentioned in the Advertisement. You acknowledge that we are not an investment advisory service, a broker-dealer or an investment adviser and we are not qualified to act as such. You acknowledge that you will consult with your own independent, tax, financial and/or legal advisers regarding any decisions as to any company mentioned here. We have not determined if the Advertisement is accurate, correct or truthful. The Advertisement is compiled from publicly available information, which include, but are not limited to, no cost online research, magazines, newspapers, reports filed with the SEC or information furnished by way of press releases. Because all information relied upon by us in preparing an advertisement about an issuer comes from a public source, it is not reliable, and you should not assume it is accurate or complete.

By your subscription to our profiles, the viewing of this profile and/or use of our website, you have agreed and acknowledged the terms of our full disclaimer and privacy policy which can be viewed at the following link: and

By accepting the Advertisement, you agree and acknowledge that any hyperlinks to the website of (1) a client company, (2) the party issuing or preparing the information for the company, or (3) other information contained in the Advertisement is provided only for your reference and convenience. The advertiser is not responsible for the accuracy or reliability of these external sites, nor is it responsible for the content, opinions, products or other materials on external sites or information sources. If you use, act upon or make decisions in reliance on information contained in any disseminated report/release or any hyperlink, you do so at your own risk and agree to hold us, our officers, directors, shareholders, affiliates and agents harmless. You acknowledge that you are not relying on the Publisher, and we are not liable for, any actions taken by you based on any information contained in any disseminated email or hyperlink.